July 24, 2024 7:48am

Make sure what and which your portfolio is holding and where it is going to be worth; as well as any share pricing costs you will have to make along the way

Pre-open Indications: 4 Negative and 2 Sell into Strength

News: Sangamo Therapeutics (SGMO +$0.01) positive topline results from the P3 AFFINE trial (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy that SGMO and Pfizer (PFE) is co-developing with and licensing to Pfizer for the treatment of adults with moderately severe to severe hemophilia A.

A daily analytic read-out from RMi is constructed of signals thought-provoking share pricing situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday

 

Wednesday: The pre-open Dow futures are DOWN -0.46% or (-165 points), the S&P futures are DOWN -0.71% or (-40 points) as the Nasdaq futures are DOWN -1.09% or (-215 points)

  • Futures traded lower Wednesday as investors were underwhelmed by quarterly reports from Alphabet and Tesla,
  • European markets lower,
  • Asia pacific markets fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed DOWN -57.35 points or -0.16%, the S&P closed DOWN -8.67 points or -0.16% while the Nasdaq closed DOWN -10.12 points or -0.06%

The CBOE Volatility Index (VIX and fear gauge)’s 10-day rate of change indicator rose to 32 last week. That marks its highest level since April.

Economic Data Docket: MBA Mortgage Applications, week ending July 19 (+3.9% prior); S&P Global US manufacturing PMI, July, preliminary (51.4 expected, 51.6 previously); S&P Global US services PMI, July, preliminary (55 expected, 55.3 previously); S&P Global US composite PMI, July, preliminary (54.8 previously); New home sales, month-over-month, June (+3.8% expected, -11.3% previously)

 

Title continued: SGMO is eligible to earn from Pfizer (PFE) up to $220 million in milestone payments upon the achievement of certain regulatory and commercial milestones for giroctocogene fitelparvovec and product sales royalties of 14% - 20% if giroctocogene fitelparvovec is approved and commercialized, subject to certain reductions.

  • Giroctocogene fitelparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV6 capsid and a modified B-domain deleted human coagulation FVIII gene. The goal of this investigational treatment for people living with hemophilia A is that a single infusion of giroctocogene fitelparvovec may allow them to produce FVIII themselves for an extended period of time, provide bleed protection and reduce the need for routine prophylaxis with intravenous (IV) infusions or injections.

 

RegMed Investors (RMi) Closing bell: “in the bag for today. Share pricing continues its incline, who’s buying – electronic trading while I believe investors are hesitant about this market’s moves and sector travels as earnings season looms.” … https://www.regmedinvestors.com/articles/13562

 

Q3/24:

  • July: 1 market holiday. 1 day off, 5 negative, 1 neutral and 9 positive closes

Q2/24: 

  • June – 1 market holiday, 7 positive and 1 negative closes
  • May – 1 holiday, 11 positive and 11 negative closes
  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Ultragenyx Pharmaceuticals (RARE) closed up +$0.72 after Monday’s +$1.91, Friday’s -$0.23, Thursday’s -$1.11 and Wednesday’s -$1.38 with a neutral aftermarket

Solid Biosciences (SLDB) closed up +$0.47 after Monday’s +$0.5, Friday’s +$0.42, Thursday’s -$1.11, and last Wednesday’s -$0.73, with a neutral aftermarket

Negative Indications:

Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed up +$3.27 after Monday’s $1.11, Friday’s +$0.48, Thursday’s -$1.47, and last Wednesday’s -$0.36, with a negative -$0.30 or -0.99% aftermarket

Verve Therapeutics (VERV) closed up =$0.52 with a negative -$0.20 or -2.60% aftermarket

Intellia Therapeutics (NTLA) closed up +$1.13 after Monday’s +$0.25, Friday’s -$1.01, Thursday’s -$1.27 and last Wednesday’s +$0.01 and Tuesday’s +$1.34 with a negative -$0.44 or -1.66% aftermarket

BioLife Solutions (BLFS) closed up +$0.66 after Friday’s -$0.43 after Thursday’s -$1.06 with a neutral aftermarket

 

The BOTTOM LINE: The 3 major indexes dived on Tuesday after closing higher on Monday.

The cell and gene therapy sector started this week well i.e., with another (Tuesday) positive close …

  • Stocks appear to shrug off worries related to the election, with the S&P 500 rising over 1% on Monday.
  • The risks aren't hard to find with the US presidential election looming.
  • A stock market pullback is more than overdue, according to some market data.
  • And a resilient economy continues to straddle the fine line between normalization from pre-pandemic trends and the start of a broader slowdown.

 

For the balance of the month, investors will focus most on share pricing in regard to earnings EPS and meeting expectations!

 

July to date: advance/decline lines and last week...

  • Tuesday’s advance/decline line ended with a positive close of 28 incliners, 4 decliners and 2 flats
  • Monday ended with a positive close of 28 incliners, 4 decliners and 3 flats
  • Friday ended with a negative close of 10 incliners, 23 decliners and 2 flats
  • Thursday ended with a negative close of 3 incliners, 30 decliners and 2 flats
  • Wednesday ended with a negative close of 4 incliners, 29 decliners and 2 flats
  • Tuesday’s advance/decline line ended with a positive close of 30 incliners, 2 decliners and 3 flats
  • (7/15) Monday ended with a positive close of 21 incliners, 9 decliners and 6 flats

 

Due “dates” are soon for Q2 LPS (loss per-share) boding releases:

  • Sage Therapeutics (SAGE) on Wednesday, 7/31
  • MiMedx (MDXG) on Wednesday, 7/31
  • Vericel (VCEL) on Thursday, 8/1
  • Alnylam Pharmaceuticals (ALNY) on Thursday, 8/1
  • Blueprint Medicine (BPMC) on Thursday, 8/1
  • Ionis Pharmaceuticals (IONS) Thursday, 8/1

 

Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts can filter out or lessen the noise of back-and-forth share pricing from sector rotation.

  • The short-term moving averages help you identify the momentum of the trend — that is, overbought or oversold

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.